TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease

Contributed by: Business Wire

Logo

Tags

Science

Neurology

Biotechnology

Research

Pharmaceutical

Health

Genetics

Clinical Trials

TreeFrog Therapeutics

More Like This

PR Newswire associated0

TREEFROG PRESENTS DATA FROM THEIR PARKINSON'S CELL THERAPY PROGRAM AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING

TreeFrog Therapeutics 10L bioreactor for cell therapy (Photo credits: TreeFrog Therapeutics)

TreeFrog Publishes Results of First Successful Bioproduction of a Parkinson’s Disease Cell Therapy in Scalable Bioreactor in Neurotherapeutics Journal

TreeFrog Therapeutics Presents Delivery Strategy for Next Generation 3D Cell Therapy Format for Parkinson’s Disease at the 28th Annual ASGCT Meeting in New Orleans

PR Newswire associated0

TREEFROG PRESENTS DATA FROM THEIR PARKINSON'S DISEASE CELL THERAPY PROGRAM AT THE 29TH WORLD CONGRESS ON PARKINSON'S DISEASE AND RELATED DISORDERS (IAPRD) IN LISBON

PR Newswire associated0

TreeFrog's Chief Scientific Officer & Co-founder, Maxime Feyeux, to present at The 23rd Congress of the Japanese Society for Regenerative Medicine (JSRM)

PR Newswire associated0

TREEFROG THERAPEUTICS PICKS-UP BEST POSTER AWARD AT THE INTERNATIONAL SOCIETY FOR CELL & GENE THERAPY (ISCT) ANNUAL MEETING FOR THEIR CELL THERAPY PROGRAM IN PARKINSON'S DISEASE

Vice-President Ambroise Fayolle, EIB and Frederic Desdouits, CEO TreeFrog Therapeutics sign financing of €30million to accelerate cell therapy programs.

TreeFrog Therapeutics Secures €30 Million From European Investment Bank (EIB) Marking a Significant Milestone in the Company’s Journey to Accelerate the Field of Cell Therapy

FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair